Downloads: 1
| # | nci_id | nct_id | official_title | inclusion_indicaInclusionor | description | Text | Boolean |
|---|---|---|---|---|---|---|---|
| 1 | NCI-2009-00336 | NCT00392327 | Efficacy of Carboplatin Administered Concomitantly with Radiation and Isotretinoin as a Pro-apoptotic Agent in Other than Average Risk Medulloblastoma/PNET Patients | Inclusion | Hemoglobin >= 8 g/dl (may be transfused) | Hemoglobin measurement greater than or equal to 8 grams per deciliter | (C64848 >= 8g/dL) |
| 2 | NCI-2009-00470 | NCT00632853 | Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer Also Receiving Cisplatin or Carboplatin and Etoposide | nan | nan | nan | nan |
| 3 | NCI-2009-00595 | NCT00719303 | Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival? | nan | nan | nan | nan |
| 4 | NCI-2009-00603 | NCT00492778 | A Randomized Trial of Pelvic Irradiation with or without Concurrent Weekly Cisplatin in Patients with Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus | nan | nan | nan | nan |
| 5 | NCI-2009-00817 | NCT00001337 | Dose-Adjusted EPOCH Chemotherapy and Rituximab (Cd20+) in Adults and Children with Previously Untreated Aggressive Non-Hodgkin's Lymphoma | nan | nan | nan | nan |
| 6 | NCI-2009-01057 | NCT00576654 | A Phase I Dose-Escalation Study of Oral ABT-888 (NSC #737664) plus Intravenous Irinotecan (CPT-11, NSC#616348) Administered in Patients with Advanced Solid Tumors | nan | nan | nan | nan |
| 7 | NCI-2011-00312 | NCT01012817 | A Phase 1/2 Trial of ABT-888, an Inhibitor of Poly(ADP-ribose) Polymerase (PARP), and Topotecan (TPT) in Patients with Solid Tumors (Phase 1) and Relapsed Ovarian Cancer or Primary Peritoneal Cancer (Phase 2) after Prior Platinum Containing First-Line Chemotherapy | Inclusion | Hemoglobin >= 9.0 g/dL | Hemoglobin measurement greater than or equal to 9 grams per deciliter | (C64848 >= 9g/dL) |
| 8 | NCI-2011-00878 | NCT00956007 | A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer | Inclusion | Hemoglobin >= 8.0 g/dL (note: the use of transfusion or other intervention to achieve hemoglobin [Hgb] >= 8.0 g/dl is acceptable) | Hemoglobin measurement greater than or equal to 8 grams per deciliter | (C64848 >= 8g/dL) |
| 9 | NCI-2011-01915 | NCT00887146 | N0577 (CODEL): Phase III Intergroup Study of Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma | Inclusion | Hemoglobin (Hgb) > 9.0 g/dL obtained =< 21 days prior to registration | Hemoglobin measurement greater than 9 grams per deciliter | (C64848 > 9g/dL) |
| 10 | NCI-2011-01972 | NCT00983697 | A Multicenter Trial of FDG-PET/CT Staging of Head and Neck Cancer and Its Impact on the N0 Neck Surgical Treatment in Head and Neck Cancer Patients | nan | nan | nan | nan |
| 11 | NCI-2011-01973 | NCT00980954 | Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy with or without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma following Radical Hysterectomy | Inclusion | Hemoglobin >= 10.0 g/dl (Note: the use of transfusion or other intervention to achieve hemoglobin [Hgb] >= 10.0 g/dl is acceptable) | Hemoglobin measurement greater than or equal to 10 grams per deciliter | (C64848 >= 10g/dL) |
| 12 | NCI-2011-01974 | NCT00981656 | A Phase II Protocol for Patients with Stage T1 Bladder Cancer to Evaluate Selective Bladder Preserving Treatment by Radiation Therapy Concurrent with Radiosensitizing Chemotherapy following a Thorough Transurethral Surgical Re-staging | Inclusion | Hemoglobin >= 10.0 g/dL (Note: the use of transfusion or other intervention to achieve hemoglobin [Hgb] >= 10.0 g/dl is acceptable) | Hemoglobin measurement greater than or equal to 10 grams per deciliter | (C64848 >= 10g/dL) |
| 13 | NCI-2011-01975 | NCT00980460 | Treatment of Children with All Stages of Hepatoblastoma with Temsirolimus (NSC#683864) Added to High Risk Stratum Treatment | nan | nan | nan | nan |
| 14 | NCI-2011-01987 | NCT01013649 | A Phase II-R and a Phase III Trial Evaluating Both Erlotinib (Ph II-R) and Chemoradiation (Ph III) as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma | nan | nan | nan | nan |
| 15 | NCI-2011-01992 | NCT02085408 | Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin & Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age >/= 60 Years) | nan | nan | nan | nan |
| 16 | NCI-2011-02000 | NCT01042522 | A Randomized Phase II Trial of Paclitaxel and Carboplatin vs. Bleomycin, Etoposide, and Cisplatin for Newly Diagnosed Advanced Stage and Recurrent Chemonaive Sex Cord-Stromal Tumors of the Ovary | nan | nan | nan | nan |
| 17 | NCI-2011-02029 | NCT01096368 | Phase III Randomized Trial of Post-radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma Ages 1 to 21 Years | nan | nan | nan | nan |
| 18 | NCI-2011-02034 | NCT01118026 | Phase II Trial of Response-Adapted Therapy Based on Positron Emission Tomography (PET) for Bulky Stage I and Stage II Classical Hodgkin Lymphoma (HL) | nan | nan | nan | nan |
| 19 | NCI-2011-02037 | NCT01101451 | Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated With Initial Radical Hysterectomy and Pelvic Lymphadenectomy | nan | nan | nan | nan |
| 20 | NCI-2011-02073 | NCT02589938 | A Phase III Prospective Randomized Trial of Acupuncture for Treatment_x000D_ of Radiation-Induced Xerostomia in Patients with Head and Neck Cancer | nan | nan | nan | nan |
| 21 | NCI-2011-02500 | NCT01366144 | An Early Phase 1 Study of ABT-888 in Combination with Carboplatin and Paclitaxel in Patients with Hepatic or Renal Dysfunction and Solid Tumors | Inclusion | Hemoglobin >= 8.0 g/dL | Hemoglobin measurement greater than or equal to 8 grams per deciliter | (C64848 >= 8g/dL) |
| 22 | NCI-2011-02515 | NCT01051635 | A Phase I Study of Indenoisoquinolines LMP400 and LMP776 in Adults with Relapsed Solid Tumors and Lymphomas | nan | nan | nan | nan |
| 23 | NCI-2011-02539 | NCT01226940 | A Phase I Trial of Lenalidomide and Radiotherapy in Children with Diffuse Intrinsic Pontine Gliomas and High-Grade Gliomas | nan | nan | nan | nan |
| 24 | NCI-2011-02592 | NCT01386385 | A Dose Finding Study Followed by Phase II Randomized, Placebo-Controlled Study of Veliparib (ABT-888) Added to Chemoradiotherapy with Carboplatin and Paclitaxel for Unresectable Stage III Non-small Cell Lung Cancer (NSCLC), (NCI Study Number 8811) | Inclusion | Hemoglobin >= 9.0 g/dl | Hemoglobin measurement greater than or equal to 9 grams per deciliter | (C64848 >= 9g/dL) |
| 25 | NCI-2011-02594 | NCT01381718 | A Phase II Placebo-Controlled Trial of Modafinil to Improve_x000D_ Neurocognitive Deficits in Children Treated for a Primary Brain Tumor | nan | nan | nan | nan |
| 26 | NCI-2011-02599 | NCT01190930 | Treatment of Patients with Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-Lineage Lymphoblastic Lymphoma (B-LLy) | nan | nan | nan | nan |
| 27 | NCI-2011-02611 | NCT01231906 | A Phase III Randomized Trial of Adding Vincristine-Topotecan-Cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non-Metastatic Ewing Sarcoma | nan | nan | nan | nan |
| 28 | NCI-2011-02623 | NCT01272037 | A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer | nan | nan | nan | nan |
| 29 | NCI-2011-02660 | NCT01275664 | Pilot Study of Standard Therapy for Prevention of Nausea and Emesis Associated with First Line Post-Operative Intraperitoneal Chemotherapy | nan | nan | nan | nan |
| 30 | NCI-2011-02673 | NCT01359592 | A Phase II Trial of PET-Directed Therapy for Limited Stage Diffuse Large B-Cell Lymphoma (DLBCL) | nan | nan | nan | nan |
| 31 | NCI-2011-02674 | NCT01368588 | Androgen Deprivation Therapy and High Dose Radiotherapy with or without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial | Inclusion | Hemoglobin (Hgb) >= 8.0 g/dL (Note: the use of transfusion or other intervention to achieve Hgb >= 8.0 g/dL is acceptable) | Hemoglobin measurement greater than or equal to 8 grams per deciliter | (C64848 >= 8g/dL) |
| 32 | NCI-2011-03458 | NCT01434316 | Phase 1 Trial of ABT-888 and SCH727965 in Patients with Advanced Solid Tumors | Inclusion | Hemoglobin (Hgb) > 9.0 g/dl | Hemoglobin measurement greater than 9 grams per deciliter | (C64848 > 9g/dL) |
| 33 | NCI-2011-03797 | NCT02883049 | A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) including a Stratum Evaluating Dasatinib (NSC#732517) in Patients with Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations | nan | nan | nan | nan |
| 34 | NCI-2012-00095 | NCT01497444 | Study of Sorafenib + TH-302: Phase I in Advanced Renal Cell Carcinoma (RCC) and Advanced Hepatocellular Carcinoma (HCC) and Phase II in 1st Line Advanced HCC | Inclusion | Hemoglobin (HgB) > 8.5 g/dL | Hemoglobin measurement greater than 8.5 grams per deciliter | (C64848 > 8.5g/dL) |
| 35 | NCI-2012-00105 | NCT01503632 | A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL | nan | nan | nan | nan |
| 36 | NCI-2012-00112 | NCT01503086 | Computerized Cognitive Training for Pediatric Brain Tumor Patients: A Pilot Study | nan | nan | nan | nan |
| 37 | NCI-2012-00234 | NCT01515787 | A Phase II/III Trial of Neoadjuvant FOLFOX, with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision | Inclusion | Hemoglobin > 8.0 g/dL | Hemoglobin measurement greater than 8 grams per deciliter | (C64848 > 8g/dL) |
| 38 | NCI-2012-00680 | NCT01333046 | Administration of Tumor-Associated Antigen (TAA)-Specific Cytotoxic T-Lymphocytes to Patients with Active or Relapsed Hodgkin or Non-Hodgkin Lymphoma | Inclusion | PROCUREMENT: Hemoglobin (Hgb) > 8.0 (transfusions allowed) | Hemoglobin measurement greater than 8 grams per deciliter | (C64848 > 8g/dL) |
| 39 | NCI-2012-00707 | NCT01556243 | Impact of Breast Conservation Surgery on Surgical Outcomes and Cosmesis in Patients with Multiple Ipsilateral Breast Cancers (MIBC) | nan | nan | nan | nan |
| 40 | NCI-2012-00719 | NCT01573442 | Randomized Double-Blind Placebo Controlled Study of Testosterone in the Adjuvant Treatment of Postmenopausal Women with Aromatase Inhibitor Induced Arthralgias | Inclusion | Hemoglobin > 11 g/dL | Hemoglobin measurement greater than 11 grams per deciliter | (C64848 > 11g/dl) |
| 41 | NCI-2012-00860 | NCT01587352 | A Phase 2 Study of Vorinostat (NSC 701852) in Metastatic Uveal Melanoma | Inclusion | Hemoglobin >= 9.0 g/dL not requiring transfusions within the past 2 weeks | Hemoglobin measurement greater than or equal to 9 grams per deciliter without a blood transfusion in past 2 weeks | C64848 >= 9g/dL AND (C15192 = NO OR C15192 > 2 wk) |
| 42 | NCI-2012-00864 | NCT01585805 | A Randomized Phase II Study of Gemcitabine, Cisplatin +/- Veliparib in Patients with Pancreas Adenocarcinoma and a Known BRCA/ PALB2 Mutation (Part I) and a Phase II Single Arm Study of Single-Agent Veliparib in Previously Treated Pancreas Adenocarcinoma (Part II) | Inclusion | Hemoglobin >= 9.0 mg/dl | Hemoglobin measurement greater than or equal to 9 milligrams per deciliter | (C64848 >= 9mg/dL) |
| 43 | NCI-2012-01040 | NCT01638533 | A Phase 1 and Pharmacokinetic Single Agent Study of Romidepsin in Patients with, Lymphomas, Chronic Lymphocytic Leukemia and Select Solid Tumors and Varying Degrees of Liver Dysfunction | Inclusion | Hemoglobin >= 9 g/dL (transfusions and/or erythropoietin are permitted) | Hemoglobin measurement greater than or equal to 9 grams per deciliter | (C64848 >= 9g/dL) |
| 44 | NCI-2012-01695 | NCT01775475 | Randomized, Phase II Trial of CHOP vs. Oral Chemotherapy with Concomitant Antiretroviral Therapy in Patients with HIV-Associated Lymphoma in Sub-Saharan Africa | Inclusion | Patients may enroll with lower hematologic values, if bone marrow involvement is documented; in this case, patients should be transfused to hemoglobin >= 8 g/dL | Hemoglobin measurement greater than or equal to 8 grams per deciliter and bone marrow involvement should transfuse to greater than or equal to 8 grams per deciliter | ( C64848 >= 8g/dL ) OR ((C8288 = YES) AND ( C64848 < 8g/dL)) |
| 45 | NCI-2012-01712 | NCT01695941 | A Phase I Study of MLN8237 in Combination with Bortezomib and Rituximab in Relapsed and Refractory Mantle Cell and Low Grade Non-Hodgkin Lymphoma | nan | nan | nan | nan |
| 46 | NCI-2012-01964 | NCT01595061 | A Phase II Trial Evaluating Cisplatin (NSC #119875) and Gemcitabine (NSC #613327) Concurrent with Intensity-Modulated Radiation Therapy (IMRT) in the Treatment of Locally Advanced Squamous Cell Carcinoma of the Vulva (NCT #01595061) | nan | nan | nan | nan |
| 47 | NCI-2012-01967 | NCT01602666 | Phase 2 Trial of Response-Based Radiation Therapy for Patients with Localized Central Nervous System Germ Cell Tumors (CNS GCT) | Inclusion | Hemoglobin >= 8.0 g/dL (may receive red blood cell [RBC] transfusions) | Hemoglobin measurement greater than or equal to 8 grams per deciliter | (C64848 >= 8g/dL) |
| 48 | NCI-2012-01977 | NCT01622868 | Phase II Randomized Study of Whole Brain Radiotherapy/Stereotactic Radiosurgery in Combination with Concurrent Lapatinib in Patients with Brain Metastasis from HER2-Positive Breast Cancer: A Collaborative Study of NRG Oncology and KROG | Inclusion | Hemoglobin >= 8.0 g/dL (note: the use of transfusion or other intervention to achieve hemoglobin [Hgb] >= 8.0 g/dL is acceptable) | Hemoglobin measurement greater than or equal to 8 grams per deciliter | (C64848 >= 8g/dL) |
| 49 | NCI-2012-01990 | NCT01649089 | Evaluation of Physical Function and Quality of Life (QOL) before and after Non-radical Surgical Therapy (Extra Fascial Hysterectomy or Cone Biopsy with Pelvic Lymphadenectomy) for Stage IA1 (LVSI+) and IA2-IB1 (≤ 2CM) Cervical Cancer | nan | nan | nan | nan |
| 50 | NCI-2012-01995 | NCT01674140 | Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer. e^3 Breast Cancer Study-Evaluating Everolimus with Endocrine Therapy. | Inclusion | Hemoglobin >= 9 g/dL | Hemoglobin measurement greater than or equal to 9 grams per deciliter | (C64848 >= 9g/dL) |
| 51 | NCI-2012-01998 | NCT01668719 | A Randomized Phase I/II Study of Optimal Induction Therapy of Bortezomib, Dexamethasone and Lenalidomide with or without Elotuzumab (NSC-764479) for Newly Diagnosed High Risk Multiple Myeloma (HRMM) | Inclusion | Uncontrolled diabetes: a glycated hemoglobin (Hg A1C) > 7% within 14 days prior to registration; the same criterion will be used in patients with confirmed diagnosis of diabetes mellitus who have been on a stable dietary or therapeutic regimen for this condition in the last three months | No uncontrolled diabetes, hemoglobin AC1 percentage must be greater than 7% | (C111207 > 7%) |
| 52 | NCI-2012-02009 | NCT01711541 | Carboplatin-Paclitaxel Induction Chemotherapy and ABT-888 (Veliparib) - a Phase 1/Randomized Phase 2 Study in Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck | nan | nan | nan | nan |
| 53 | NCI-2012-02011 | NCT01711554 | A Phase I Study of Lenalidomide and Anti-GD2 Mab Ch14.18 +/- Isotretinoin in Patients with Refractory/Recurrent Neuroblastoma | Inclusion | Hemoglobin >= 8.0 (may transfuse) | Hemoglobin measurement greater than or equal to 8 grams per deciliter | (C64848 >= 8g/dL) |
| 54 | NCI-2012-02020 | NCT01781468 | A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil®) to Reduce Cancer-Related Fatigue in Patients with High Grade Glioma | Exclusion | profound anemia (hemoglobin level of < 10 g/dL =< 28 days prior to registration) | Hemoglobin measurement less than 10 grams per deciliter | (C64848 >= 10g/dL) |
| 55 | NCI-2012-02045 | NCT01805076 | Effect of Preoperative Breast MRI on Surgical Outcomes, Costs and Quality of Life of Women with Breast Cancer | nan | nan | nan | nan |
| 56 | NCI-2012-02057 | NCT01730937 | Randomized Phase III Study of Sorafenib Versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma | Inclusion | Hemoglobin >= 8.0 g/dl (Note: the use of transfusion or other intervention to achieve hemoglobin [Hgb] >= 8.0 g/dl is acceptable) | Hemoglobin measurement greater than or equal to 8 grams per deciliter | (C64848 >= 8g/dL) |
| 57 | NCI-2012-02067 | NCT01349881 | A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer, Phase III- Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES) | Inclusion | Hemoglobin > 11.0 g/dL | Hemoglobin measurement greater than 11 grams per deciliter | (C64848 >= 11g/dL) |
| 58 | NCI-2012-02078 | NCT01789684 | A Cluster Randomized Controlled Trial Comparing Interventions to Enhance Utilization of Genetics_x000D_ Services Among Breast Cancer Patients | nan | nan | nan | nan |
| 59 | NCI-2012-02608 | NCT01863550 | Randomized Phase III Trial of Bortezomib, LENalidomide and Dexamethasone (VRd) versus Carfilzomib, Lenalidomide, Dexamethasone (CRd) Followed by Limited or Indefinite DURation Lenalidomide MaintenANCE in Patients with Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE) | Inclusion | STEP I: Hemoglobin >= 8 g/dL | Hemoglobin measurement greater than or equal to 8 grams per deciliter | (C64848 >= 8g/dL) |
| 60 | NCI-2012-02767 | NCT01749397 | A Phase I Trial of the Combination of the PARP Inhibitor ABT-888 with Intraperitoneal Floxuridine (FUDR) in Epithelial Ovarian, Primary Peritoneal and Fallopian Tube Cancers | Inclusion | Hemoglobin (Hgb) > 9.0 mg/dl | Hemoglobin measurement greater than or equal to 9 grams per deciliter | (C64848 >= 9g/dL) |
| 61 | NCI-2012-02869 | NCT01806129 | EROS: Engendering Reproductive Health within Oncologic Survivorship | nan | nan | nan | nan |
| 62 | NCI-2012-02875 | NCT01586403 | Transfer of Genetically Engineered Lymphocytes in Melanoma Patients: A Phase 1 Dose Escalation Study | nan | nan | nan | nan |
| 63 | NCI-2012-03124 | NCT01755195 | A Phase 2 Study of Cabozantinib (XL184), a Dual Inhibitor of MET and VEGFR, in Patients with Metastatic Refractory Soft Tissue Sarcoma | Inclusion | Hemoglobin >= 9 g/dL | Hemoglobin measurement greater than or equal to 9 grams per deciliter | (C64848 >= 9g/dL) |
| 64 | NCI-2012-03125 | NCT01767194 | A Phase II Randomized Trial of Irinotecan/Temozolomide with Temsirolimus (NSC# 683864) or Chimeric 14.18 Antibody (Ch14.18) (NSC# 764038) in Children with Refractory, Relapsed or Progressive Neuroblastoma | nan | nan | nan | nan |
| 65 | NCI-2012-03173 | NCT01089101 | A Phase 1 and Phase II and Re-Treatment Study of AZD6244 for Recurrent or Refractory Pediatric Low Grade Glioma | Inclusion | Hemoglobin >= 8 g/dL (may be supported) | Hemoglobin measurement greater than or equal to 8 grams per deciliter | (C64848 >= 8g/dL) |
| 66 | NCI-2012-03198 | NCT01872975 | A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy | nan | nan | nan | nan |
| 67 | NCI-2013-00046 | NCT01771107 | A Pilot Trial of AVD and Brentuximab Vedotin (SGN-35) in the Treatment of Stage II-IV HIV-Associated Hodgkin Lymphoma | nan | nan | nan | nan |
| 68 | NCI-2013-00370 | NCT01220583 | A Randomized Phase II / Phase III Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors | Inclusion | Hemoglobin >= 8.0 g/dl (Note: the use of transfusion or other intervention to achieve hemoglobin [Hgb] >= 8.0 g/dl is acceptable) | Hemoglobin measurement greater than or equal to 8 grams per deciliter | (C64848 >= 8g/dL) |
| 69 | NCI-2013-00426 | NCT01824836 | A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS) | nan | nan | nan | nan |
| 70 | NCI-2013-00500 | NCT01810913 | Randomized Phase II/III Trial of Surgery and Postoperative Radiation Delivered with Concurrent Cisplatin versus Docetaxel versus Docetaxel and Cetuximab for High-Risk Squamous Cell Cancer of the Head and Neck | Inclusion | Hemoglobin >= 8.0 g/dl (Note: the use of transfusion or other intervention to achieve hemoglobin [Hgb] >= 8.0 g/dl is acceptable) | Hemoglobin measurement greater than or equal to 8 grams per deciliter | (C64848 >= 8g/dL) |
| 71 | NCI-2013-00595 | NCT01817075 | Impact of Cleansing with Chlorhexidine Gluconate (CHG) on Reducing Central Line Associated Bloodstream Infection (CLABSI) and Acquisition of Multi-drug Resistant Organisms (MDRO) in Children with Cancer or Those Receiving Allogeneic Hematopoietic Cell Transplantation (HCT) | nan | nan | nan | nan |
| 72 | NCI-2013-00716 | NCT00978250 | Multi-Histology Phase II Study of 5-Fluoro-2'-Deoxycytidine with Tetrahydrouridine (FdCyd + THU) | nan | nan | nan | nan |
| 73 | NCI-2013-00737 | NCT01822496 | A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-small Cell Lung Cancer (NSCLC) | Inclusion | Hemoglobin >= 8.0 g/dl (Note: the use of transfusion or other intervention to achieve hemoglobin [Hgb] >= 8.0 g/dl is acceptable) | Hemoglobin measurement greater than or equal to 8 grams per deciliter | (C64848 >= 8g/dL) |
| 74 | NCI-2013-00739 | NCT01822509 | A Phase I/Ib Study of Ipilimumab or Nivolumab in Patients with Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation | nan | nan | nan | nan |
| 75 | NCI-2013-00740 | NCT01822522 | Phase I Trial of Cabozantinib (XL184) for Advanced Solid Tumors in Persons with HIV Infection | Inclusion | Hemoglobin >= 9 g/dL | Hemoglobin measurement greater than or equal to 9 grams per deciliter | (C64848 >= 9g/dL) |
| 76 | NCI-2013-00805 | NCT01244737 | A Phase II Study of [18F] FLT for PET Imaging of Brain Tumors in Children | nan | nan | nan | nan |
| 77 | NCI-2013-00826 | NCT01841723 | A Multicenter Phase 2 Study of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 (Ibrutinib) for Treatment of Relapsed Hairy Cell Leukemia | Inclusion | Hemoglobin < 11 g/dL | Hemoglobin measurement less than 11 grams per deciliter | (C64848 < 11g/dL) |
| 78 | NCI-2013-00858 | NCT01849146 | Phase I Study of AZD1775 (MK-1775) with Radiation and Temozolomide in Patients with Newly Diagnosed Glioblastoma and Evaluation of Intratumoral Drug Distribution in Patients with Recurrent Glioblastoma | Inclusion | Hemoglobin >= 9 g/dL | Hemoglobin measurement greater than or equal to 9 grams per deciliter | (C64848 >= 9g/dL) |
| 79 | NCI-2013-00875 | NCT01901094 | A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease after Neoadjuvant Chemotherapy | nan | nan | nan | nan |
| 80 | NCI-2013-00877 | NCT01851369 | A Phase I/II Trial of TRC102 (Methoxyamine HCl) in Combination with Temozolomide in Patients with Relapsed Solid Tumors and Lymphomas | Inclusion | Hemoglobin >= 12 g/dL | Hemoglobin measurement greater than or equal to 12 grams per deciliter | (C64848 >= 12g/dL) |
| 81 | NCI-2013-00877 | NCT01851369 | A Phase I/II Trial of TRC102 (Methoxyamine HCl) in Combination with Temozolomide in Patients with Relapsed Solid Tumors and Lymphomas | Inclusion | Hemoglobin >= 10 g/dL without transfusion within 4 days prior to enrollment | Hemoglobin measurement greater than or equal to 10 grams per deciliter without transfusion | ((C64848 >= 10g/dL) AND C15192=NO OR C15192 > 4d) |
| 82 | NCI-2013-00890 | NCT01935934 | A Phase 2 Study of XL184 (Cabozantinib) in Recurrent or Metastatic Endometrial Cancer | Inclusion | Hemoglobin >= 90 g/L | Hemoglobin measurement greater than or equal to 90 grams per liter | (C64848 >= 90g/L) |
| 83 | NCI-2013-00998 | NCT01881867 | A Phase 2 Study of Recombinant Glycosylated Human Interleukin-7 (CYT107) after Completion of Standard FDA Approved Therapy with Sipuleucel-T (Provenge®) for Patients with Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Inclusion | Hemoglobin >= 10 g/dL | Hemoglobin measurement greater than or equal to 10 grams per deciliter | (C64848 >= 10g/dL) |
| 84 | NCI-2013-01132 | NCT01534598 | Phase I Trial of Oral 5-Fluoro-2'-Deoxycytidine with Oral Tetrahydrouridine in Patients with Advanced Solid Tumors | nan | nan | nan | nan |
| 85 | NCI-2013-01272 | NCT01897012 | A Phase 1 Trial of MLN8237 plus Romidepsin for Relapsed/Refractory Aggressive B-Cell and T-Cell Lymphomas | nan | nan | nan | nan |
| 86 | NCI-2013-01275 | NCT01896999 | A Phase I Study with an Expansion Cohort/Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab, and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma | nan | nan | nan | nan |
| 87 | NCI-2013-01320 | NCT01902173 | Phase I/II Study of the Safety and Efficacy of the AKT Inhibitor GSK2141795 in Combination with Dabrafenib and Trametinib in Patients with BRAF Mutant Cancer | Inclusion | Hemoglobin >= 9 g/dL | Hemoglobin measurement greater than or equal to 9 grams per deciliter | (C64848 >= 9g/dL) |
| 88 | NCI-2013-01340 | NCT01953588 | ALTernate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer NeoAdjuvant TrEatment (ALTERNATE) in Postmenopausal Women: A Phase III Study | nan | nan | nan | nan |
| 89 | NCI-2013-01357 | NCT01912625 | A Phase 1 Study of Trametinib in Combination with Chemoradiation for KRAS Mutant Non-small Cell Lung Cancer | Inclusion | Hemoglobin >= 9 g/dL | Hemoglobin measurement greater than or equal to 9 grams per deciliter | (C64848 >= 9g/dL) |
| 90 | NCI-2013-01368 | NCT01925131 | A Phase I Study of Inotuzumab Ozogamicin (NSC-772518) in Combination with CVP (Cyclophosphamide, Vincristine, Prednisone) for Patients with Relapsed/Refractory CD22-Positive Acute Leukemia (including B-ALL, Mixed Phenotypic Leukemia and Burkitt's Leukemia) | nan | nan | nan | nan |
| 91 | NCI-2013-01452 | NCT00942877 | Phase II Study of Cediranib (AZD2171) in Patients with Alveolar Soft Part Sarcoma | nan | nan | nan | nan |
| 92 | NCI-2013-01474 | NCT01273155 | Phase I Pharmacokinetic Study of Belinostat for Solid Tumors and Lymphomas in Patients with Varying Degrees of Hepatic Dysfunction | nan | nan | nan | nan |
| 93 | NCI-2013-01475 | NCT01273168 | Phase I Trial of Z-Endoxifen in Adults with Refractory Hormone Receptor-Positive Breast Cancer, Desmoid Tumors, Gynecologic Tumors, or Other Hormone Receptor-Positive Solid Tumors | nan | nan | nan | nan |
| 94 | NCI-2013-01491 | NCT01362803 | A Phase I/II Study of the Mitogen Activated Protein Kinase Kinase (MEK) 1 Inhibitor Selumetinib (AZD6244; HYD Sulfate) in Children with Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN) | Inclusion | Hemoglobin >= 9 g/dl | Hemoglobin measurement greater than or equal to 9 grams per deciliter | (C64848 >= 9g/dL) |
| 95 | NCI-2013-01496 | NCT01391962 | A Phase II Trial in Which Patients with Metastatic Alveolar Soft Part Sarcoma Are Randomized to Either Sunitinib or Cediranib Monotherapy, with Cross-Over at Disease Progression | Inclusion | Hemoglobin >= 9 g/dL | Hemoglobin measurement greater than or equal to 9 grams per deciliter | (C64848 >= 9g/dL) |
| 96 | NCI-2013-01520 | NCT01572493 | A Phase I Study of a Continuous Intravenous Infusion of Recombinant Human IL-15 (rhIL-15) in Adults with Metastatic Cancers | nan | nan | nan | nan |
| 97 | NCI-2013-01568 | NCT01748825 | A Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Inhibitor, in Patients with Advanced Refractory Solid Tumors | Inclusion | Hemoglobin > 9 g/dL | Hemoglobin measurement greater than or equal to 9 grams per deciliter | (C64848 >= 9g/dL) |
| 98 | NCI-2013-01588 | NCT01827384 | Molecular Profiling-Based Assignment of Cancer Therapy for Patients with Advanced Solid Tumors | nan | nan | nan | nan |
| 99 | NCI-2013-01602 | NCT01922076 | A Phase 1 Study of AZD1775 (MK-1775, IND# 116495) Concurrent with Local Radiation Therapy for the Treatment of Newly Diagnosed Children with Diffuse Intrinsic Pontine Gliomas | nan | nan | nan | nan |
| 100 | NCI-2013-01639 | NCT01964300 | Phase II Study of Peginterferon Alfa-2b (SYLATRON) for Pediatric Patients with Unresectable or Recurrent Craniopharyngioma | Inclusion | Hemoglobin (Hg) >= 8g/dL (unsupported) | Hemoglobin measurement greater than or equal to 8 grams per deciliter without transfusion | ((C64848 >= 8g/dL) AND (C15192 = NO)) = YES |